ACE2 of the heart: From angiotensin I to angiotensin (1-7)

Cardiovascular Research

Volumn 73, Issue 3, 2007, Pages 463-469

  Keidar, Shlomo ^a   Kaplan, Marielle ^a   Gamliel Lazarovich, Aviva ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

ACE; ACE2; Angiotensin (1 7); Angiotensin II; Heart

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN[1-7]; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LENTIVIRUS VECTOR; LISINOPRIL; LOSARTAN; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; OLMESARTAN; RENIN; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; GENE OVEREXPRESSION; GENETIC MANIPULATION; HEART; HEART FAILURE; HEART FUNCTION; HEART HYPERTROPHY; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART OUTPUT; HEART PROTECTION; HORMONE ACTION; HORMONE METABOLISM; HORMONE RECEPTOR INTERACTION; HUMAN; HYDROLYSIS; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TISSUE SPECIFICITY; VASOCONSTRICTION; VASODILATATION;

ANGIOTENSIN I; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIUM; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RECEPTOR, ANGIOTENSIN, TYPE 1; VENTRICULAR REMODELING;

EID: 33846256550     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2006.09.006     Document Type: Review

References (67)

1. Ferrario C.M., Brosnihan K.B., Diz D.I., Jaiswal N., Khosla M.C., Milsted A., et al. Angiotensin-(1-7): a new hormone of the angiotensin system. Hypertension 18 (1991) III126-III133 [Suppl]
2. Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87 (2000) E1-E9
3. Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., and Turner A.J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275 (2000) 33238-33243
4. Oudit G.Y., Crackower M.A., Backx P.H., and Penninger J.M. The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med 13 (2003) 93-101
5. Danilczyk U., Eriksson U., Crackower M.A., and Penninger J.M. A story of two ACEs. J Mol Med 81 (2003) 227-234
6. Urata H., Kinoshita A., Misono K.S., Bumpus F.M., and Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 265 (1990) 22348-22357
7. Roks A.J.M., Buikema H., Pinto Y.M., and van Gilst W.H. The renin-angiotensin system and vascular function: the role of angiotensin II, angiotensin-converting enzyme, and alternative conversion of angiotensin I. Heart Vessels suppl 12 (1997) 119-124
8. Wu Q., Kuo H.C., and Deng G.G. Serine proteases and cardiac function. Biochim Biophys Acta 1751 (2005) 82-94
9. Touyz R.M. The role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep 5 (2003) 155-164
10. Schelling P., Fischer H., and Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy?. J Hypertens 9 (1991) 3-15
11. Touyz R.M., Tabet F., and Schiffrin E.L. Redox-dependent signaling by angiotensin II and vascular remodeling in hypertension. Clin Exp Pharmacol Physiol 30 (2003) 860-866
12. Vaughan D.E. Angiotensin, fibrinolysis, and vascular homeostasis. Am J Cardiol 19 87 (2001) 18C-24C
13. Lijnen P.J., Petrov V.V., and Fagard R.H. Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptors. J Renin Angiotensin Aldosterone Syst 2 (2001) 117-122
14. Masaki H., Kurihara T., Yamaki A., Inomata N., Nozawa Y., Mori Y., et al. Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects. J Clin Invest 101 (1998) 527-535
15. Horiuchi M., Akishita M., and Dzau V.J. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 33 (1999) 613-621
16. Levy B.I. How to explain the differences between renin angiotensin system modulators. Am J Hypertens 18 (2005) 134S-141S
17. Serneri G.G., Boddi M., Cecioni I., Vanni S., Coppo M., Papa M.L., et al. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res 88 (2001) 961-968
18. Kaicimi R., and Gerdes A.M. Alteration in G protein and MAP kinase signaling pathways during cardiac remodeling in hypertension and heart failure. Hypertension 41 (2003) 968-977
19. Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J., et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277 (2002) 14838-14843
20. Reudelhuber T.L. A place in our hearts for the lowly angiotensin 1-7 peptide?. Hypertension 47 (2006) 811-815
21. Rice G.I., Thomas D.A., Grant P.J., Turner A.J., and Hooper N.M. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 383 (2004) 45-51
22. Zisman L.S., Keller R.S., Weaver B., Lin Q., Speth R., Bristow M.R., et al. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation 108 (2003) 1707-1712
23. Keidar S., Gamliel-Lazarovich A., Kaplan M., Pavlotzky E., Hamoud S., Hayek T., et al. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res 97 (2005) 946-953
24. Ocaranza M.P., Godoy I., Jalil J.E., Varas M., Collantes P., Pinto M., et al. Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension 48 (2006) 572-578
25. Li N., Zimpelmann J., Cheng K., Wilkins J.A., and Burns K.D. The role of angiotensin converting enzyme 2 in the generation of angiotensin 1-7 by rat proximal tubules. Am J Physiol Renal Physiol 288 (2005) F353-F362
26. Shaltout H.A., Westwood B., Averill D.B., Ferrario C.M., Figueroa J., Diz D.I., et al. Angiotensin metabolism in renal proximal tubules, urine and serum of sheep: evidence for ACE2-dependent processing of angiotensin II. Am J Physiol Renal Physiol (Aug 8 2006) [Electronic publication ahead of print]
27. Santos R.A., Brosnihan K.B., Jacobsen D.W., DiCorleto P.E., and Ferrario C.M. Production of angiotensin-(1-7) by human vascular endothelium. Hypertension 19 2 Suppl (1992) II56-II61
28. Yamamoto K., Chappell M.C., Brosnihan K.B., and Ferrario C.M. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 19 (1992) 692-696
29. Chappell M.C., Tallant E.A., Brosnihan K.B., and Ferrario C.M. Conversion of angiotensin I to angiotensin-(1-7) by thimet oligopeptidase (EC 3.4.24.15) in vascular smooth muscle cells. J Vasc Med Biol 5 (1994) 129-137
30. Santos R.A., Simoes e Silva A.C., Maric C., Silva D.M., Machado R.P., de Buhr I., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100 (2003) 8258-8263
31. Kostenis E., Milligan G., Christopoulos A., Sanchez-Ferrer C.F., Heringer-Walther S., Sexton P.M., et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 111 (2005) 1806-1813
32. Castro C.H., Santos R.A., Ferreira A.J., Bader M., Alenina N., and Almeida A.P. Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart. Hypertension 46 (2005) 937-942
33. Pinheiro S.V., Simoes e Silva A.C., Sampaio W.O., de Paula R.D., Mendes E.P., Bontempo E.D., et al. Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension 44 (2004) 490-496
34. Le Tran Y., and Forster C. Angiotensin-(1-7) and the rat aorta: modulation by the endothelium. J Cardiovasc Pharmacol 30 (1997) 676-682
35. Ren Y., Garvin J.L., and Carretero O.A. Vasodilator action of angiotensin 1-7 (Ang 1-7) in the isolated afferent arteriole of the rabbit kidney. J Am Soc Nephrol 9 (1998) 345A
36. Sampaio W.O., Nascimento A.A., and Santos R.A. Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am J Physiol Heart Circ Physiol 284 (2003) H1985-H1994
37. Ueda S., Masumori-Maemoto S., Ashino K., Nagahara T., Gotoh E., Umemura S., et al. Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man. Hypertension 35 (2000) 998-1001
38. Davie A.P., and McMurray J.J. Effect of angiotensin-(1-7) and bradykinin in patients with heart failure treated with an ACE inhibitor. Hypertension 34 (1999) 457-460
39. Mahon J.M., Carr R.D., Nicol A.K., and Henderson I.W. Angiotensin(1-7) is an antagonist at the type 1 angiotensin II receptor. J Hypertens 12 (1994) 1377-1381
40. Pörsti I., Bara A., Busse R., and Hecker M. Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol 111 (1994) 652-654
41. Brosnihan K.B., Li P., and Ferrario C.M. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27 (1996) 523-528
42. Paula R.D., Lima C.V., Khosla M.C., and Santos R.A. Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension 26 (1995) 1154-1159
43. Ueda S., Masumori-Maemoto S., Wada A., Ishii M., Brosnihan K.B., and Umemura S. Angiotensin(1-7) potentiates bradykinin-induced vasodilatation in man. J Hypertens 19 (2001) 2001-2009
44. Roks A.J., van Geel P.P., Pinto Y.M., Buikema H., Henning R.H., de Zeeuw D., et al. Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension 34 (1999) 296-301
45. Osei S.Y., Ahima R.S., Minkes R.K., Weaver J.P., Khosla M.C., and Kadowitz P.J. Differential responses to Ang-(1-7) in the feline mesenteric and hindquarter vascular beds. Eur J Pharmacol 234 (1993) 35-42
46. Zisman L.S., Meixell G.E., Bristow M.R., and Canver C.C. Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate. Circulation 108 (2003) 1679-1681
47. Santos R.A., Brum J.M., Brosnihan K.B., and Ferrario C.M. The renin-angiotensin system during acute myocardial ischemia in dogs. Hypertension 15 (1990) I121-I127 [Suppl]
48. Averill D.B., Ishiyama Y., Chappell M.C., and Ferrario C.M. Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation 108 (2003) 2141-2146
49. Loot A.E., Roks A.J., Henning R.H., Tio R.A., Suurmeijer A.J., Boomsma F., et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 105 (2002) 1548-1550
50. Santos R.A., Castro C.H., Gava E., Pinheiro S.V., Almeida A.P., Paula R.D., et al. Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension 47 (2006) 996-1002
51. Kittleson M.M., Minhas K.M., Irizarry R.A., Ye S.Q., Edness G., Breton E., et al. Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure. Physiol Genomics 21 (2005) 299-307
52. Lieb W., Graf J., Gotz A., Konig I.R., Mayer B., Fischer M., et al. Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA Augsburg echocardiographic substudy. J Mol Med 84 (2006) 88-96
53. Burrell L.M., Risvanis J., Kubota E., Dean R.G., MacDonald P.S., Lu S., et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 26 (2005) 369-375
54. Ishiyama Y., Gallagher P.E., Averill D.B., Tallant E.A., Brosnihan K.B., and Ferrario C.M. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43 (2004) 970-976
55. Crackower M.A., Sarao R., Oudit G.Y., Yagil C., Kozieradzki I., Scanga S.E., et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417 (2002) 822-828
56. Yamamoto K., Ohishi M., Katsuya T., Ito N., Ikushima M., Kaibe M., et al. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 47 (2006) 718-726
57. Dales N.A., Gould A.E., Brown J.A., Calderwood E.F., Guan B., Minor C.A., et al. Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. J Am Chem Soc 124 (2002) 11852-11853
58. Huang L., Sexton D.J., Skogerson K., Devlin M., Smith R., Sanyal I., et al. Novel peptide inhibitors of angiotensin-converting enzyme 2. J Biol Chem 278 (2003) 15532-15540
59. Tikellis C., Cooper M.E., Bialkowski K., Johnston C.I., Burns W.C., Lew R.A., et al. Developmental expression of ACE2 in the SHR kidney: a role in hypertension?. Kidney Int 70 (2006) 34-41
60. Ye M., Wysocki J., Naaz P., Salabat M.R., LaPointe M.S., and Batlle D. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination?. Hypertension 43 (2004) 1120-1125
61. Donoghue M., Wakimoto H., Maguire C.T., Acton S., Hales P., Stagliano N., et al. Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins. J Mol Cell Cardiol 35 9 (Sep 2003) 1043-1053
62. Lin Q., Keller R.S., Weaver B., and Zisman L.S. Interaction of ACE2 and integrin beta 1 in failing human heart. Biochim Biophys Acta 1689 (2004) 175-178
63. Huentelman M.J., Grobe J.L., Vazquez J., Stewart J.M., Mecca A.P., Katovich M.J., et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 90 (2005) 783-790
64. Gottlieb S.S., Dickstein K., Fleck E., Kostis J., Levine T.B., LeJemtel T., et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 88 (1993) 1602-1609
65. Iyer S.N., Ferrario C.M., and Chappell M.C. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 31 (1998) 356-361
66. Ferrario C.M., Jessup J., Chappell M.C., Averill D.B., Brosnihan K.B., Tallant E.A., et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111 (2005) 2605-2610
67. Igase M., Strawn W.B., Gallagher P.E., Geary R.L., and Ferrario C.M. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 289 (2005) H1013-H1019